Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Cirrhosis

Free Subscription 22.04.2024 1 BMC Cancer 1 BMC Gastroenterol 1 Clin Res Hepatol Gastroenterol 5 Dig Dis Sci 1 Gut 14 Hepatology 1 Intern Med 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. HAO X, Xu L, Lan X, Li B, et al
   Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy.
   BMC Cancer. 2024;24:475.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

2. KRANIDIOTI H, Zisimopoulos K, Oikonomou T, Voulgaris T, et al
   Successful therapy with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) does not guarantee amelioration of liver damage assessing by transient elastography. A retrospective - prospective multicenter study.
   BMC Gastroenterol. 2024;24:133.
   PubMed         Abstract available
   
   

   
   Clin Res Hepatol Gastroenterol

3. PATEL K, Twohig P, Peeraphatdit T, Stohs EJ, et al
   Outcomes and factors associated with cryptococcal disease among cirrhotics: A study of the national inpatient sample 2005 to 2014.
   Clin Res Hepatol Gastroenterol. 2024;48:102337.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

4. MCCURDY H, Nobbe A, Scott D, Patton H, et al
   Organizational and Implementation Factors Associated with Cirrhosis Care in the Veterans Health Administration.
   Dig Dis Sci. 2024 Apr 14. doi: 10.1007/s10620-024-08409.
   PubMed         Abstract available
   
   
5. KHAMSEH ME, Malek M, Jahangiri S, Nobarani S, et al
   Insulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver Fibrosis.
   Dig Dis Sci. 2024;69:1430-1443.
   PubMed         Abstract available
   
   
6. CON D, Tu S, Clayton-Chubb D, Lubel JS, et al
   Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
   Dig Dis Sci. 2024 Feb 20. doi: 10.1007/s10620-024-08354.
   PubMed         Abstract available
   
   
7. WILLIAMS EE, Mladenovic A, Ranginani D, Weber R, et al
   Role of Spleen Stiffness Measurement in the Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease.
   Dig Dis Sci. 2024;69:1444-1453.
   PubMed         Abstract available
   
   
8. BEHARI J
   Spleen Stiffness Measurement in Metabolic Dysfunction-Associated Steatotic Liver Disease-Value Added or Work in Progress?
   Dig Dis Sci. 2024;69:1093-1095.
   PubMed        
   
   

   
   Gut

9. LIU J, MacNaughtan J, Kerbert AJC, Portlock T, et al
   Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis.
   Gut. 2024 Apr 15:gutjnl-2023-330699. doi: 10.1136/gutjnl-2023-330699.
   PubMed         Abstract available
   
   

   
   Hepatology

10. AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
    Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
    Hepatology. 2024;79:1098-1106.
    PubMed         Abstract available
    
    
11. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
    Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
    PubMed         Abstract available
    
    
12. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
    Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
    Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
    PubMed         Abstract available
    
    
13. PREMKUMAR M, Kajal K, Reddy KR, Izzy M, et al
    Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000691.
    PubMed         Abstract available
    
    
14. GISH RG, Jacobson IM, Lim JK, Waters-Banker C, et al
    Prevalence and characteristics of Hepatitis delta virus infection in patients with hepatitis b in the united states: An analysis of the All-Payer Claims Database.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000687.
    PubMed         Abstract available
    
    
15. DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
    Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:1107-1116.
    PubMed         Abstract available
    
    
16. DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
    Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hepatology. 2024;79:E146-E147.
    PubMed        
    
    
17. LIU H, Li H, Wang DX, Li T, et al
    Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:E144-E145.
    PubMed        
    
    
18. WIEGAND J, Franke A, Stein K, Trautwein C, et al
    Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
    PubMed        
    
    
19. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
    Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
    PubMed        
    
    
20. VOLK ML
    Innovations in Healthcare Delivery for Patients with Cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
    PubMed        
    
    
21. GARCIA-TSAO G, Kaplan DE
    Reply: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
    PubMed        
    
    
22. PRZYBYSZEWSKI EM, Bhan I, Yarze JC
    Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
    PubMed        
    
    
23. GUO C, Liu Z, Fan H, Wang H, et al
    Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
    Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
    PubMed         Abstract available
    
    

    
    Intern Med

24. HARA Y, Yanagita T, Ishii K, Nakamura K, et al
    Portal Vein Thrombosis Caused by Miliary Tuberculosis.
    Intern Med. 2024;63:1181-1182.
    PubMed        
    
    

    
    PLoS One

25. CHAVEZ-TAPIA NC, Sanchez-Jimenez BA, Vidana-Perez D, Corrales-Rosas B, et al
    Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study.
    PLoS One. 2024;19:e0290632.
    PubMed         Abstract available
    
    
26. GURUN M, Brennan P, Handjiev S, Khatib A, et al
    Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.
    PLoS One. 2024;19:e0299507.
    PubMed         Abstract available
    
    
27. PASTROVIC F, Novak R, Grgurevic I, Hrkac S, et al
    Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.
    PLoS One. 2024;19:e0301416.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.